IP Library Granted Patent US 8,383,106
Granted Patent B2
US 8,383,106 · App. 12/909,769 · Granted Feb 26, 2013

Materials and methods for improved immunoglycoproteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,106
App. No.
12/909,769
Granted
Feb 26, 2013
Kind
B2
Abstract

Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.

Claims (11)

1. A composition comprising recombinant immunoglycoprotein molecules, wherein the recombinant immunoglycoprotein molecules each comprise an N-linked glycosylation site for linkage of oligosaccharide, and wherein at least 60% of the N-linked oligosaccharides of the N-linked glycosylation site have a hexose content of at least ten hexose molecules.

2. The composition of claim 1 , wherein the immunoglycoprotein molecules exhibit at least 5-fold higher ADCC compared to control immunoglycoprotein molecules of the same encoded amino acid sequence produced in CHO-K1 cells in the absence of a carbohydrate modifier.

3. The composition of claim 1 , wherein at least 60% of the N-linked oligosaccharides of the N-linked glycosylation site contain no fucose.

4. The composition of claim 1 formulated in a pharmaceutically acceptable carrier or diluent.

5. The composition of claim 4 , wherein the composition is sterile.

6. The composition of claim 1 comprising at least 100 g of immunoglycoprotein molecules and a pharmaceutically acceptable carrier or diluent.

7. The composition of claim 1 comprising at least 100 liters of culture medium.

8. The composition of any one of claims 1 - 3 , wherein the recombinant immunoglycoprotein molecules are bispecific in antigen-binding.

9. The composition of any one of claims 1 - 3 , wherein the recombinant immunoglycoprotein molecules are trispecific in antigen-binding.

10. The composition of any one of claims 1 - 3 , wherein the recombinant immunoglycoprotein molecule is an antibody or a small modular immunopharmaceutical.

11. The composition of claim 10 , wherein the small modular immunopharmaceutical comprises amino acids 24-496 of SEQ ID NO:2.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: APTEVO THEAPEUTICS INC.; APTEVO BIOTHERAPEUTICS LLC; APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 052039/0258 →
SECURITY INTEREST Recorded Feb 7, 2019
From: APTEVO THERAPEUTICS INC.; APTEVO BIOTHERAPEUTICS INC.; APTEVO RESEARCH AND DEVELOPMENT LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 048270/0813 →
CHANGE OF NAME Recorded Jul 18, 2016
From: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
To: APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 039382/0985 →
MERGER Recorded Dec 21, 2010
From: TRUBION PHARMACEUTICALS, INC.
To: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
Reel/Frame 025532/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2010
From: BAUM, PETER ROBERT; ESPLING, ERIK STEPHEN; THOMPSON, PETER ARMSTRONG
To: TRUBION PHARMACEUTICALS, INC.
Reel/Frame 025356/0526 →